T32-supported Immunology and Rheumatology Postdoctoral Fellows will undertake two years of training in either translational research in clinical immunology or in clinical investigation. Applicants for T32 support will be M.D., Ph.D. or M.D./Ph.D. degree holders. Candidates for postdoctoral fellowships will be reviewed and selected by a Postdoctoral Committee composed of representatives of the two Rheumatology Divisions. The clinical years of postdoctoral fellowship in rheumatology for MDs, not covered by T32 funding will predominantly consist of attendance at outpatient clinics, as well as inpatient consulting. Following clinical training, trainees will select one of two Research Tracks for their T32 training: (i.) The Clinical Immunology Translational Research Track (Track 1);or (ii.) The Clinical Investigation (Track 2). The training in Track 1 will be available for those fellows interested in pursuing translational research in clinical immunology and will be supplemented with required and recommended coursework. A two-year training program in Track 2 can lead to a Master's of Science Degree, administered through the Department of Health Research and Policy. It is our belief that such formal training is important for trainees who pursue a career in clinical research, to provide a foundation in the fundamentals of clinical trial design, bioethics, data analysis, and other important issues in clinical research. For all trainees in both Tracks, attendance will be required at weekly lectures in rheumatic diseases, as well as a series of lectures on Responsible Conduct of Research. Postdoctoral trainees are expected to attend weekly Immunology Grand Rounds, Journal Club meetings, the weekly Immunology Seminar Series, and the Annual T32 and Immunology Retreats during all years of training. This will provide interactions between the rheumatology fellows and the many other immunology fellows and students involved in research endeavors at Stanford. In the T32-supported years, MD postdoctoral fellows will attend clinic one or two half-days per week, as well as regular research meetings determined by their individual preceptors. We will leverage Stanford's rich environment to provide many additional opportunities for trainees interested in immunology, proteomics, genomics, clinical trials, and outcomes.
In order to meet future public health needs of the nation this educational training program provides exceptional research training to M.D., M.D./Ph.D., or Ph.D. trainees in adult and pediatric rheumatology and clinical immunology. It will train the next generation of translational and clinical research investigators to take advantage of new breakthroughs in understanding disease pathophysiology and the resultant potential for innovative therapy in both adult and pediatric rheumatic diseases. The long-term goal is to enable the trainees to become independent investigators and academic physician- scientist leaders of the future.
|Lee, Lori W; Narang, Neera S; Postolova, Anna et al. (2016) Anti-MDA5-Positive Dermatomyositis Presenting as Fever of Unknown Origin. J Gen Intern Med 31:1530-1536|
|Corey, Daniel M; Rosental, Benyamin; Kowarsky, Mark et al. (2016) Developmental cell death programs license cytotoxic cells to eliminate histocompatible partners. Proc Natl Acad Sci U S A 113:6520-5|
|Wagner, Catriona A; Sokolove, Jeremy; Lahey, Lauren J et al. (2015) Identification of anticitrullinated protein antibody reactivities in a subset of anti-CCP-negative rheumatoid arthritis: association with cigarette smoking and HLA-DRB1 'shared epitope' alleles. Ann Rheum Dis 74:579-86|
|Yip, Linda; Fuhlbrigge, Rebecca; Taylor, Cariel et al. (2015) Inflammation and hyperglycemia mediate Deaf1 splicing in the pancreatic lymph nodes via distinct pathways during type 1 diabetes. Diabetes 64:604-17|
|Hansmann, Leo; Blum, Lisa; Ju, Chia-Hsin et al. (2015) Mass cytometry analysis shows that a novel memory phenotype B cell is expanded in multiple myeloma. Cancer Immunol Res 3:650-60|
|Nasrallah, Mazen; Pouliot, Yannick; Hartmann, Bjoern et al. (2015) Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment. Arthritis Res Ther 17:262|
|Fiorentino, David F; Kuo, Karen; Chung, Lorinda et al. (2015) Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1Î³ antibodies in adults with dermatomyositis. J Am Acad Dermatol 72:449-55|
|Qi, Qian; Zhang, David W; Weyand, Cornelia M et al. (2014) Mechanisms shaping the naÃ¯ve T cell repertoire in the elderly - thymic involution or peripheral homeostatic proliferation? Exp Gerontol 54:71-4|
|Ronis, Tova; Frankovich, Jennifer; Yen, Sophia et al. (2014) Pilot study of reproductive health counseling in a pediatric rheumatology clinic. Arthritis Care Res (Hoboken) 66:631-5|
|Chung, Lorinda; Ball, Katharine; Yaqub, Aaliya et al. (2014) Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: results of a prospective pilot study. J Am Acad Dermatol 71:400-1|
Showing the most recent 10 out of 28 publications